Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Asian Pac J Cancer Prev ; 25(2): 563-573, 2024 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-38415543

RESUMO

OBJECTIVE: The study's aim was to evaluate Brazilian Brown Propolis (BBP) and Artepillin C (ARC) chemopreventive action in Wistar rats' colons. METHODS: Fifty male Wistar rats were divided into ten experimental groups, including control groups, groups with and without 1,2-dimethylhydrazine (DMH) induction, and BBP, ARC, and ARC enriched fraction (EFR) treatments, for sixteen weeks. Aberrant crypt foci (ACF) were classified as hyperplastic or dysplastic, and proliferating cell nuclear antigen (PCNA) expression was quantified. RESULT: ACF amounts in experimental groups (induced or not) decreased in both colon portions, while the isolated Aberrant Crypt (AC) number increased. Experimental groups of animals showed higher hyperplasia and dysplasia amounts compared with control groups. The ACF dysplastic amount present in groups induced and treated, in both colon portions, had similar values to IDMH (DMH induction group without treatment). In addition, DMH was effective in ACF inducing and there was positive staining for PCNA in basal and upper dysplastic foci portions in all experimental groups, in the mitotic index (MI) evaluation. To conclude, considering all the experimental groups, the one treated with EFR (fraction enriched with ARC) had the lowest rates of cell proliferation. CONCLUSION: BBP and its derivatives prevented crypt cell clonal expansion.


Assuntos
Focos de Criptas Aberrantes , Antineoplásicos , Neoplasias do Colo , Fenilpropionatos , Própole , Ratos , Animais , Masculino , Ratos Wistar , Neoplasias do Colo/tratamento farmacológico , Antígeno Nuclear de Célula em Proliferação/metabolismo , Própole/farmacologia , Própole/uso terapêutico , 1,2-Dimetilidrazina/toxicidade , Brasil , Focos de Criptas Aberrantes/tratamento farmacológico , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Carcinógenos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...